↓ Cooling
Business
The Surprising Reason This Biotech Plummeted 69%
Eyepoint Pharmaceuticals stock has plummeted 69% following a late-stage trial failure for its wet AMD drug, DURAVYU.
Eyepoint Pharmaceuticals
1 trends tracked about this subject — the full history, oldest to newest below.